Results 41 to 50 of about 106,545 (283)

Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. [PDF]

, 2019
Dasatinib, a second-generation BCR-ABL1 tyrosine kinase inhibitor, is approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, both as first-line therapy and after imatinib intolerance or ...
Abruzzese, Elisabetta, Cortes, Jorge E, Hochhaus, Andreas, Hughes, Timothy P, Laneuville, Pierre, Lipton, Jeffrey H, Paar, David, Rea, Delphine, Rousselot, Philippe, Shah, Neil P, Snyder, David S   +10 more
core   +2 more sources

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

The effects of time valuation in cancer optimal therapies: a study of chronic myeloid leukemia [PDF]

, 2019
Background The mathematical design of optimal therapies to fight cancer is an important research field in today’s Biomathematics and Biomedicine given its relevance to formulate patient-specific treatments. Until now, however, cancer optimal therapies
Gutiérrez Díez, Pedro José
core   +2 more sources

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients [PDF]

, 2018
open25noSecond-generation tyrosine kinase inhibitors (2G-TKIs) dasatinib and nilotinib produced historical rates of about 50% complete cytogenetic response (CCyR) and about 40% major molecular response (MMR) in chronic myeloid leukaemia (CML) patients ...

core   +1 more source

In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells

BMC Cancer, 2010
Background Breast cancer treatment is based on a combination of adjuvant chemotherapy followed by radiotherapy effecting intracellular signal transduction. With the tyrosine kinase inhibitors new targeted drugs are available.
Weigel Marion T, Dahmke Linda, Schem Christian, Bauerschlag Dirk O, Weber Katrin, Niehoff Peter, Bauer Maret, Strauss Alexander, Jonat Walter, Maass Nicolai, Mundhenke Christoph   +10 more
doaj   +1 more source

Automated Iterative N─C and C─C Bond Formation

Angewandte Chemie, EarlyView.
Automated iterative assembly of MIDA or TIDA boronate building blocks enables generalized and automated preparation of many different types of small functional molecules in a modular fashion. However, until now, this engine could not leverage nitrogen atoms as iteration handles, excluding molecules rich in N─C and C─C bonds.
Theodore Tyrikos‐Ergas, Sevasti Agiakloglou, Antonio J. LaPorte, Wesley Wang, Chieh‐Kai Chan, Clare E. Wells, Christopher K. Rakowski, Rachel I. Hammond, Jia Qiu, Jonathan D. Raymond, Tiago Vieira, John Limanto, Marc N. Feiglin, Daniel J. Blair, Martin D. Burke   +14 more
wiley   +2 more sources

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV

Haematologica, 2019
Standard first-line therapy of chronic myeloid leukemia is treatment with imatinib. In the randomized German Chronic Myeloid Leukemia-Study IV, more potent BCR-ABL inhibition with 800 mg (‘high-dose’) imatinib accelerated achievement of a deep molecular ...
Christian Michel, Andreas Burchert, Andreas Hochhaus, Susanne Saussele, Andreas Neubauer, Michael Lauseker, Stefan W. Krause, Hans-Jochem Kolb, Dieter Kurt Hossfeld, Christoph Nerl, Gabriela M. Baerlocher, Dominik Heim, Tim H Brümmendorf, Alice Fabarius, Claudia Haferlach, Brigitte Schlegelberger, Leopold Balleisen, Maria-Elisabeth Goebeler, Mathias Hänel, Anthony Ho, Jolanta Dengler, Christiane Falge, Robert Möhle, Stephan Kremers, Michael Kneba, Frank Stegelmann, Claus-Henning Köhne, Hans-Walter Lindemann, Cornelius F. Waller, Karsten Spiekermann, Wolfgang E. Berdel, Lothar Müller, Matthias Edinger, Jiri Mayer, Dietrich W. Beelen, Martin Bentz, Hartmut Link, Bernd Hertenstein, Roland Fuchs, Martin Wernli, Frank Schlegel, Rudolf Schlag, Maike de Wit, Lorenz Trümper, Holger Hebart, Markus Hahn, Jörg Thomalla, Christof Scheid, Philippe Schafhausen, Walter Verbeek, Michael J. Eckart, Winfried Gassmann, Michael Schenk, Peter Brossart, Thomas Wündisch, Thomas Geer, Stephan Bildat, Erhardt Schäfer, Joerg Hasford, Rüdiger Hehlmann, Markus Pfirrmann   +60 more
doaj   +1 more source

Imatinib inhibits VEGF-independent angiogenesis by targeting neuropilin 1-dependent ABL1 activation in endothelial cells. [PDF]

, 2014
To enable new blood vessel growth, endothelial cells (ECs) express neuropilin 1 (NRP1), and NRP1 associates with the receptor tyrosine kinase VEGFR2 after binding the vascular endothelial growth factor A (VEGF) to enhance arteriogenesis.
Alessandro Fantin, Anastasia Lampropoulou, Anissa Chikh, Anselmi, Ballmer-Hofer, Baruzzi, Birukova, Buchdunger, Campochiaro, Carmeliet, Casanovas, Chen, Chen, Chislock, Cho, Choi, Christiana Ruhrberg, Clark, Claudio Raimondi, Colicelli, Connor, Cui, Cujec, Dejana, Druker, Fantin, Fantin, Fantin, Fantin, Foxton, Fukasawa, Gerhardt, Gerhardt, Herzog, Kawamura, Kawasaki, Kim, Kitsukawa, Koch, Lanahan, Lanahan, Laura Denti, Lewis, Lewis, Mamluk, Murga, Nishijima, Pan, Pan, Parsons, Pasapera, Phng, Raimondi, Ren, Robinson, Roig, Rosenfeld, Ruhrberg, Ruhrberg, Saint-Geniez, Salikhova, Shimizu, Shojaei, Smith, Soker, Sottile, Stenzel, Tvorogov, Uemura, Valdembri, Wang, Welti, Yaqoob, Zaidel-Bar, Zhuang   +74 more
core   +4 more sources

Imatinib

Japanese Journal of Clinical Immunology, 2009
The progress in molecular targeting therapy includes two tides, namely, small molecule compounds and large molecule biological agents. Although the latter prevails in the field of clinical immunology, the former attracts more and more attention in these few years.
openaire   +3 more sources

Reintroduction of Imatinib in GIST [PDF]

Journal of Gastrointestinal Cancer, 2013
Abstract Purpose This review examines the clinical evidence showing that imatinib can be prescribed to treat recurrence or progression of gastrointestinal stromal tumors (GIST) in patients who interrupted first-line imatinib therapy in the adjuvant or advanced/metastatic setting ...
openaire   +3 more sources